Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers. 11 papers were listed this time. Here's a handful in our areas of research interest:
Montero AJ, Avancha K, Glück S, et al. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. Breast Cancer Res Treat. 2011 Dec 27. [Epub ahead of print] PubMed PMID: 22200867.
Anokye NK, Trueman P, Green C, Pavey TG, Hillsdon M, Taylor RS. The cost-effectiveness of exercise referral schemes. BMC Public Health. 2011 Dec 26;11(1):954. [Epub ahead of print] PubMed PMID: 22200193.
van Gils PF, Over EA, Hamberg-van Reenen HH, et al. The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population. BMJ Open. 2011 Dec 21;1(2):e000363. Print 2011. PubMed PMID: 22189351.
